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Abstract
Swine influenza virus (SIV) has a strong tropism for pig respiratory mucosa, which consists of a mucus layer, epithelium,
basement membrane and lamina propria. Sialic acids present on the epithelial surface have long been considered to be
determinants of influenza virus tropism. However, mucus which is also rich in sialic acids may serve as the first barrier of
selection. It was investigated how influenza virus interacts with the mucus to infect epithelial cells. Two techniques were
applied to track SIV H1N1 in porcine mucus. The microscopic diffusion of SIV particles in the mucus was analyzed by single
particle tracking (SPT), and the macroscopic penetration of SIV through mucus was studied by a virus in-capsule-mucus
penetration system, followed by visualizing the translocation of the virions with time by immunofluorescence staining.
Furthermore, the effects of neuraminidase on SIV getting through or binding to the mucus were studied by using zanamivir,
a neuraminidase inhibitor (NAI), and Arthrobacter ureafaciens neuraminidase. The distribution of the diffusion coefficient
shows that 70% of SIV particles were entrapped, while the rest diffused freely in the mucus. Additionally, SIV penetrated the
porcine mucus with time, reaching a depth of 65 mm at 30 min post virus addition, 2 fold of that at 2 min. Both the
microscopic diffusion and macroscopic penetration were largely diminished by NAI, while were clearly increased by the
effect of exogenous neuraminidase. Moreover, the exogenous neuraminidase sufficiently prevented the binding of SIV to
mucus which was reversely enhanced by effect of NAI. These findings clearly show that the neuraminidase helps SIV move
through the mucus, which is important for the virus to reach and infect epithelial cells and eventually become shed into the
lumen of the respiratory tract.
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Introduction
Pigs are naturally susceptible to three subtypes of influenza A
viruses: H1N1, H3N2 and H1N2, all of which have a strong
tropism for the pig respiratory tract mucosa [1–3]. Swine influenza
virus particles are transmitted by direct contact and through the
air in large droplets or as aerosols [1,4,5]. During the transmission
from pig to pig, the virus first encounters mucus, the first barrier of
the respiratory tract. After overcoming this barrier, the virus
reaches the target cells in the mucosal epithelium. Influenza virus
infects host cells by binding to cellular receptors via one of the
major viral glycoproteins, hemagglutinin (HA). HA binds to sialic
acids (SA) on the cell surface and mediates the subsequent
membrane fusion leading to virus entry [6]. Neuraminidase (NA)
catalyzes the removal of terminal sialic acids on the cellular surface
to release the progeny virus [7]. It is well documented that the NA
functions at the releasing stage of the virus replication [8–10],
while little is known if NA plays a role during the virus entry into
host cells and even less on if it helps the virus overcome the mucus
layer.
Mucus is a complex mixture of mucous glycoproteins (mucins),
proteins, proteases and protease inhibitors, lipids and water
[11,12]. Mucins, the major component of mucus, are highly o-
glycosylated with glycans covalently linked via N-acetylgalactosa-
mine (GaNAc) to the hydroxyl groups of serine and threonine
residues of the mucin backbone [12,13]. Most of the sugar chains
of mucin monomers are terminated with sialic acid, which is also
known to be the cellular receptor of influenza viruses. It is
hypothesized that influenza viruses bind to these extracellular
receptors, get entrapped in the mucus and then are removed by
ciliary clearance [14–16]. Several studies have shown that
interaction of influenza virus with mucus results in competitive
inhibition of the virus. Roberts et al. [17] showed that pre-
incubation of human H3N2 virus strain A/Victoria/3/75 with
ferret nasal washes containing mucus clearly reduced the virus
infectivity, and this inhibition was correlated to competitive
binding of the virus with alpha 2,3 and 2,6 linked sialic acids
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(a2,3- and a2,6-SA) present in the mucus secretions. The
protective effect of the mucus barrier was confirmed by a recent
study using a transgenic mouse model that overexpressed SA a2-3
Gal rich Muc5AC. Transgenic mice challenged with A/PR8/34
H1N1, which preferentially binds a2,3-SA showed significant less
infection than the normal mice [18]. These studies suggest that
mucus or mucins block the influenza virus infection by compet-
itively inhibiting HA-mediated cell adsorption.
Despite this inhibitory function of the mucus, the virus is
ultimately able to reach the susceptible epithelial cells. It has long
been assumed that NA promotes virus access to target cells in the
airway by mucus degradation. However, this concept is scarcely
supported by experimental data. Cohen et al. [19] incubated A/
PR/8/34 H1N1 and A/Aichi/2/68 H3N2 virus with human
salivary mucins which were previously coated on magnetic beads,
and after extensive washings, detected the remained Neu5AC on
the mucins. They showed that these human influenza viruses had
cleaved away 40–60% of Neu5AC content of the mucins by their
viral neuraminidase. The effective cleavage may allow the efficient
release of virus from the mucus. This contrasts with the findings of
Ehre et al. [18] who demonstrated a strong protection of Muc5AC
up-regulated mice against A/PR/8/34 H1N1 virus infection.
Hence, the purified human salivary mucins may not fully reflect
the natural mucus as these mucins had been highly modified after
attaching to magnetic beads. Unraveling the mechanism behind
the penetration of viruses across the mucosal barriers has
potentially significant implications for the development of novel
antiviral strategies. Therefore, an in vitro model resembling the in
vivo situation is needed and the interactions of influenza virus with
natural mucus should be studied in depth. In the present study, we
aimed to address the following questions:
(1) Is the virus entrapped or able to penetrate through the
native respiratory mucus?
(2) Can viral neuraminidase use mucin sialic acids as
substrates and catalyze the cleavage of them away?
(3) Is this cleavage sufficient to liberate the virions and allow
them to penetrate through the mucus layer?
To this purpose, we applied swine influenza virus to a model we
previously set up using porcine respiratory mucus, pseudorabies
virus (PRV) and single particle tracking (SPT) [20]. In addition,
the penetration of SIV was studied by the use of a mucus layer on
which an appropriate amount of virus particles was added. The
microscopic diffusion and macroscopic translocation were evalu-
ated. Next, the effects of neuraminidase on the virus mobility in
mucus were examined.
Materials and Methods
Mucus sample collection
Tracheas were collected from 6-month-old pigs which were
negative for swine influenza A viruses as shown by a Hemagglu-
tination Inhibition (HI) test. Using of tracheas from euthanized
animals was approved by the Ethical and Animal Welfare
Committee of the Faculty of Veterinary Medicine of Ghent
University. Two days before euthanization, the pigs were treated
intramuscularly with ceftiofur (Naxcel, Pfizer-1 ml/20 kg body
weight) to clear the respiratory tract from possible bacterial
infections. The tracheas were dissected and the mucus was gently
scraped with a spoon, collected with a syringe, and the mucus
samples were stored separately at 270uC until use. These samples
were negative for neuraminidase determined by NA assay using
fluorescent NA substrate (4-methylumbelliferyl-N-acetylneurami-
nic acid [MU-NANA]).
Fluorescence lectin staining of a2,3- and a2,6-SA in
mucus
Freshly collected mucus was filled in a gelatin capsule (2.3 cm6
0.8 cm), snap frozen in methocel (Fluka). Cryosections of 12 mm
were made with a trimming interval of 400 mm between each
section. The mucus sections were blocked in 1% (w/v) bovine
serum albumin for 1 h, followed by incubation with biotin
conjugated Sambucus nigra lectin (SNA-I) (EY laboratory, CA,
USA; 1:100) for 1 h, at room temperature. After 2 washings in
phosphate buffered saline (PBS), the sections were incubated with
Streptavidin-Texas Red (Invitrogen, 1:200) and FITC labeled
Maackia amurensis lectin (MAA) (EY laboratory, CA, USA; 1:25)
for 1 h, at room temperature. Afterwards, the sections were
washed, and mounted in 90% glycerin containing 2.5% 1,4-
diazobicyclo-(2,2,2)-octane (DABCO). Images of the fluorescence
staining were acquired using a confocal microscope (Leica TCS
SP2 Laser scanning spectral confocal system, Leica microsystems
GmbH) and the fluorescence signal was analyzed with ImageJ.
The coverage of either SA was calculated by ratio of fluorescence
signal to the region of interest (ROI).
Cells and virus
Madin Darby Canine Kidney (MDCK) cells were maintained in
Minimum Essential Medium (MEM, Gibco) supplemented with
10% fetal calf serum (Gibco), 100 mg/ml of streptomycin and
100 units/ml of penicillin (Invitrogen). The avian-like H1N1 swine
influenza virus Sw/Belgium/1/98 was used at the third passage on
MDCK cells. The virus was propagated in MDCK cells in MEM
supplemented with 5 mg/ml trypsin (Gibco), 100 mg/ml of
streptomycin and 100 units/ml of penicillin (Gibco).
Purification of SIV
Confluent MDCK cells were inoculated with SIV at a
multiplicity of infection (m.o.i) of 0.01 in MEM. Twenty hours
post inoculation, the supernatant was harvested. The cellular
debris was removed by ultracentrifugation at 7 0006g for 20 min
at 4uC in a Type 35 rotor (Beckman, Fullerton, CA, USA) and the
suspension was clarified by filtration with a 0.45 mm filter
(Millipore). Afterwards, the virus was pelleted at 75 000 6g for
2 h at 4uC in a type 35 rotor. Following resuspension in PBS (1/
100 of the original volume), the virus suspension was brought on a
discontinuous OptiPrep (Sigma) gradient containing 10–30% (w/
v) of iodixanol and centrifuged at 100 0006g for 3 h at 4uC in an
SW41Ti rotor (Beckman, Fullerton, CA, USA). The visible
opalescent virus bands at the interfaces were harvested separately.
The buffer was exchanged with HNE (5 mM HEPES, 150 mM
NaCl, 0.1 mM EDTA, pH 7.4) buffer by the use of a 50 kDa filter
device (Millipore).
Verification of the viral purity by lipophilic labeling and
immunofluorescence staining of SIV antigens
To verify the purity of the virus from each band, double staining
was performed by using 3,39-Dioctadecyloxacarbocyanine per-
chlorate (Dio) and hyperimmune swine serum directed to
influenza Sw/Belgium/1/98 virus, followed by Texas Red-
conjugated goat anti-swine IgG antibody. Hyperimmune swine
serum was diluted (1:50) and mixed with the virus suspension (1:1,
v/v). After 2 h incubation on ice, Texas Red-conjugated goat anti-
swine IgG secondary antibody (1:50, Invitrogen) was added and
incubated further on ice for 2 h. Afterwards, the resulting mixture
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containing virus, hyperimmune serum, and secondary antibody
was equilibrated to room temperature. Dio solution (1 mM in
DMSO) was mixed with virus suspension (1:100, v/v) by fierce
vortexing, followed by incubation at room temperature for
20 min. The resulting suspension was ultracentrifuged at 100
0006g for 1.5 h in a type 35 rotor to remove the free antibodies
and dyes. After resuspension in PBS, the virions were clarified by a
further ultracentrifugation at 100 0006g for 1.5 h. The staining
was analyzed with confocal microscope by randomly selecting 10
regions. The ratio of viral antigen positive particles (virions) versus
Dio positive particles was calculated, which is referred to as the
degree of viral purity.
Characteristic analysis of the Dio-labeled SIV
The band containing the most purified virus was obtained and
the buffer was exchanged with HNE buffer. After incubation with
Dio solution as previously described, the virus suspension was
filtered by the use of a Sephadex G-50 column (GE Healthcare,
Belgium) to remove unbound dye. The unlabeled virus that was
eluted through the Sephadex G-50 column was used as negative
control. Dio is a lipophilic dye which integrates into the lipid
components of the viral envelope. To determine that the
integration of the Dio dye into the viral envelope does not change
the biophysical properties of the virus, the size and surface charge
(zeta potential) of the labeled and unlabeled virions were measured
by dynamic light scattering and laser Doppler anemometry as
previously described [20]. Infectivity and hemagglutination
activity of the Dio-labeled viral particles were tested by virus
titration and HA assay as previously described [21]. The NA
enzymatic activity was determined according to the protocol
adapted from Adamo et al. [22]. Briefly, 25 ml of fluorescent NA
substrate (4-methylumbelliferyl-N-acetylneuraminic acid [MU-
NANA], 100 mM in PBS, pH 7.4) was added to 25 ml of each
sample containing 16 HA units. After 1 h incubation at 37uC,
reactions were stopped with 0.1 M glycine (pH 10.7) in 25%
ethanol. Controls and standards were run in parallel, and the
fluorescence was measured on a Victor V (Perkin Elmer,
Waltham, MA) at an excitation of 360 nm and an emission of
430 nm for 0.1 s per well.
Microscopic diffusion of SIV in mucus determined by SPT
The trajectories of fluorescent viral particles in porcine tracheal
respiratory mucus were recorded by a fast and sensitive electron-
multiplying charge-coupled device (EMCCD) camera (Cascade II:
512; Roper Scientific, Tucson, AZ, USA) mounted on an inverted
epifluorescence microscope (Nikon TE2000E, Nikon Belux,
Brussels, Belgium) equipped with a 1006 oil-immersion objective
(Plan Apochromat, Nikon). Tracking experiments were performed
in press-to-seal silicone isolators (20 mm diameter, 0.5 mm deep,
Invitrogen, Merelbeke, Belgium). Our previous study shows that
PRV was highly immobilized while 100 nm PGEylated beads
were diffusive in porcine respiratory mucus, hence GFP-PRV was
used as a negative control and the latter was used as a positive
control [20]. GFP-PRV was semi-purified according to the
previous protocol [20]. Three microliters of SIV (108.5 TCID50/
ml) or PRV (108.5 TCID50/ml) suspension or 100 nm PEGylated
beads (0.004%, w/v) were mixed with 100 ml of porcine tracheal
respiratory mucus by gentle stirring. To determine if NA would
affect SIV diffusion, the virus was added to the mucus with or
without the presence of 0.02 mM zanamivir (Sigma) or 10 mU/ml
Arthrobacter ureafaciens neuraminidase (Roche Applied Science).
The mixture was placed in a custom made glass chamber. The
samples were incubated at 37uC for 10 min on the microscope
using a stage-top incubator (Tokai Hit, Fujinomiya, Japan) before
SPT measurement. Movies were captured with the NIS Elements
AR software (Nikon) at a temporal resolution of 33 ms for 5 s. The
illumination time was 30 ms per frame. Trajectories of n $ 500
particles were analyzed for each experiment and three indepen-
dent experiments were performed for each condition. Movies were
analyzed with the Image Processing Software (IPS, in-house
developed software) [23] to extract x, y positional data over time.
The apparent diffusion coefficient (Da) was calculated as a
function of the time scale (t) for each particle. Analysis of the
movies was performed with IPS. The centroids of individual
particles were identified in each frame of a movie. Based on the
positions of the centroids, the trajectories of the particles can be
determined by a nearest neighbor algorithm. The apparent
diffusion coefficient Da corresponding to the first time lag Dt
was calculated according to the classical formula: Da = MSD/4Dt
[24]. Afterwards, the distribution of diffusion coefficient of the
particles was obtained by maximum entropy method (MEM)
analysis [25].
Penetration of SIV in porcine respiratory mucus
Freshly collected mucus sample (150 ml) was added to a gelatin
capsule (2.3 cm60.8 cm) to create a mucus ‘‘layer’’ at the bottom
(referred to as virus in-capsule-mucus penetration system, Fig. 1).
Afterwards, eight microliter of virus suspension containing
approximately 106.5 TCID50 purified SIV were brought in the
form of 5 droplets onto the surface of the mucus. Immediately,
10 min and 30 min after virus addition, the capsules were snap
frozen in methocel. Due to a delay of freezing process, the time
point ‘‘immediately after addition’’ was designated as 2 min. To
determine if the NA would influence the SIV penetration, the virus
was added with or without the presence of 0.1 mM Zanamivir
(Sigma) or 50 mU/ml Arthrobacter ureafaciens neuraminidase
onto the mucus, followed by snap-freezing at 30 min post virus
addition. Cryosections of 12 mm were made with a trimming
interval of 400 mm between each section. Double immunofluo-
rescence staining was performed using mouse anti-Muc5AC IgG1
(45M1, LifeSpan Biosciences, 1:100) and mouse anti-NP IgG2a
(HB-65, ATCC, 1:50) monoclonal antibodies, followed by Texas
Red conjugated goat anti-mouse IgG1 and Alexa Fluor 488
conjugated goat anti-mouse IgG2a secondary antibodies (Invitro-
gen), respectively. Ten sections were made for each condition,
then 10 images were taken, and finally translocations of the virions
was measured, as shown in Fig. 1, from the top of the mucus layer
until the deepest point of the viral signal.
Effects of NA on SIV binding to porcine respiratory
mucus
Mucus sections (12 mm) were made, and incubated with 30 ml
suspension containing 106 TCID50 SIV in the presence or absence
of 0.1 mM zanamivir or 50 mU/ml Arthrobacter ureafaciens
neuraminidase at 37uC, for 1 h. The sections were then fixed with
4% paraformaldehyde for 20 min, followed permeabilization in
0.1% (v/v) Triton X-100 for 10 min. Immunofluorescence
staining was performed using a mouse IgG antibody to SIV NP,
followed by Goat anti-mouse IgG antibody conjugated with FITC
to visualize the virions. Fluorescence images were acquired on
randomly selected regions with a confocal microscope, and the
bound virions on the mucus were calculated with ImageJ.
Results
SAs distribution in porcine respiratory mucus
Five sections were examined for each mucus sample for the
semi-quantification of a2,3- and a2,6-SA coverage in the mucus.
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For each section, 2 images were taken and thus 10 images were
obtained for each sample. As shown in Fig. 2, the mucus consisted
of mixed and heterogeneous a2,3- and a2,6-SA. The SA coverage
was calculated by the ratio of the pixels of positive signal to the
total pixels measured. The a2,6-SA covered over 50% the region
of interest (ROI), while merely 11% of the region was constituted
by a2,3-SA.
SIV purity assessed by double staining
After ultracentrifugation over a discontinuous OptiPrep gradi-
ent containing 10% to 30% of iodixanol, three visible opalescent
bands were collected, named Band 1, Band 2 and Band 3,
respectively, from top to bottom (Fig. 3B). The purity of virus from
each band was assessed by confocal microscopy following Dio
lipophilic dye labeling and SIV immunofluorescence staining. As
Dio integrates into the lipophilic components of virus and cellular
debris, Dio staining was used as a total-particle assessment. The
red color visualized the viral particles, and the green color
represented Dio-labeled particles (Fig. 3A). The percentage of
double positive particles versus Dio positive particles represents the
virus purity in a ratio extent. Consequently, the highest viral purity
(over 0.9 for the ratio of double positive particles/Dio positive
particles) was found in Band 2 (Fig. 3C). Therefore, the virus
preparation from Band 2 was used for further analysis.
Characterization of Dio-labeled SIV
After incubation with 10 mM Dio dye at room temperature,
followed by elution in a Sepharose G-50 column, the labeled and
unlabeled SIV were analyzed for different characteristics. The
results show that the hemagglutination activity and infectivity were
not altered by labeling. The neuraminidase activity of Dio-labeled
SIV was 91% of that of unlabeled SIV. Measured by dynamic
light scattering and laser Doppler anemometry, the size and
surface charge of the labeled virions were not significantly altered
(Table 1).
SIV was partially diffusive in porcine respiratory mucus
The motion of SIV in porcine respiratory mucus was
investigated and compared with the diffusion of PRV and
100 nm PEGylated beads. Trajectories of 8 steps were analyzed,
from which a distribution of the apparent diffusion coefficients was
obtained. Similar to our previous data, PRV was highly hindered
in the porcine respiratory mucus, while the 100 nm PEGylated
beads diffused freely. The distribution of diffusion coefficient
clearly demonstrated that, compared to one immobile fraction for
PRV or a mobile fraction for the 100 nm beads, SIV experienced
two diffusion patterns in porcine respiratory mucus, with 70% of
viral particles being trapped while the rest of particles moving
rapidly (Fig. 4A). The average diffusion coefficient of SIV in
mucus was 11-fold higher than that of PRV (Fig. 4B). The similar
size 100 nm PEGylated beads are muco-innert which indicates
that these particles did not interact with any type of the mucus
moieties. Thus to the opposite, the viral particles were immobi-
lized probably due to binding interactions with the mucus. These
data suggest that binding and releasing effects were present in the
interactions of SIV with porcine respiratory mucus.
Penetration of SIV through the mucus layer
The depth of SIV penetration could be visualized by double
immunofluorescence staining of the Muc5AC and SIV nucleo-
protein (NP). The distance from the surface down to the deepest
point of virus translocation was measured and designated as the
depth of virus penetration (Fig. 1). Three independent experi-
ments were performed and in total 120 measurements were
conducted. Distribution of the penetration depth for each
condition was eventually obtained. Immediately after virus
addition, the virions rapidly entered the mucus layer and reached
a depth of 31 mm within 2 min, due to a passive diffusion effect
(Fig. 5A). Incubated at 37uC, the virions spread further in the
mucus with time. The distribution of penetration depth shows that
the majority of SIV particles travelled 10 mm further in the mucus
from 2 until 10 min after virus addition and reached a depth of up
to 180 mm at 30 min after addition (Fig. 5A). Similarly to the
microscopic diffusion, the distribution of SIV penetration clearly
Figure 1. Schematic procedure of virus in-capsule-mucus penetration system. (1) 150 ml of mucus were brought at the bottom of a gelatin
capsule. (2) 8 ml of SIV suspension were added on top of the surface of the mucus. (3) Mucus together with virus was embedded and snap-frozen. (4)
Cryosections were made vertically to the mucus surface. (5) Immunofluorescence staining was performed to visualize the Muc5AC (representing the
mucus) and viral particles. (6) Penetration depth (shown by yellow arrows) was measured from the surface of mucus to the furthest point of the viral
signal.
doi:10.1371/journal.pone.0110026.g001
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shows two fractions at 30 min after virus addition (Fig. 5B). About
65% of the viral particles penetrated at 30 min more than 2-fold
further than 2 min post virus addition (Fig. 5B). The average
depth of virus penetration at 30 min was significantly higher than
that of earlier time points (Fig. 5C), suggesting that the SIV virions
were able to actively penetrate the mucus layer.
Neuraminidase mediated the diffusion and penetration
of SIV in respiratory mucus
Movies were captured with SPT software, and the SIV
microscopic diffusion in mucus in the presence or absence of
zanamivir or exogenous neuraminidase was analyzed with IPS. As
shown in Fig. 6A, the mobile fraction of SIV diffusion was severely
diminished by NAI treatment, while was elevated by the addition
of Arthrobacter ureafaciens neuraminidase. Approximately 55% of
the mobile viral particles (with Da larger than 0.2 mm2/s) became
stuck by the effect of zanamivir whereas the exogenous
neuraminidase increased the mobile particles by approximately
15% (Fig. 6B). Consistently, the presence of zanamivir in virus
suspension almost completely inhibited the SIV macroscopic
penetration which contrasts the further penetration by the effect of
exogenous neuraminidase (Fig. 6C). The average penetration of
mock treated SIV was significantly higher than that of NAI treated
virus, while the rise of average penetration from mock to
neuraminidase treated virus was also significant (Fig. 6D). These
data imply that neuraminidase helped SIV penetrate through the
porcine respiratory mucus.
Effects of NA on SIV binding to the porcine respiratory
mucus
Virus attaching to the mucus sections was visualized by
immunofluorescence staining to the SIV NP. The virus binding
to 5 mucus sections was analyzed, 2 images were taken for each
section and in total 10 images were obtained for virions
quantification. The virions that attached to a mucus region of
105 mm2 were calculated. Three independent experiments were
performed. The representative confocal photomicrographs show
that zanamivir clearly enhanced the attachment of SIV to the
mucus. In contrast, the exogenous neuraminidase depleted the
virus binding to the mucus by 2-fold (Fig. 7). These data clearly
demonstrated that NA was able to release the SIV particles which
may have been bound by interaction of HA with mucins, moving
the virions through the mucus.
Discussion
Influenza viruses are highly contagious and readily spread by
aerosol transmission. The mucus is the first barrier for the small
aerosol droplets to settle and overcome. In the present study, we
applied SPT technique and a custom made virus in-capsule-mucus
penetration system to visualize the microscopic diffusion and
macroscopic penetration of SIV in porcine respiratory mucus.
SPT is a unique model for rigorous analysis of virus-mucus
interactions from the mobility point of view. The virus in-capsule-
mucus penetration system allows the visualization of virus
penetration in mucus layer thereby mimicking the natural
Figure 2. Expression of a2,3- and a2,6-SA on porcine respiratory mucus determined by fluorescence lectin staining. (A)
Representative confocal microscopy images. Green color shows a2,3-SA staining and red color represents a2,6-SA staining. The scale bars indicate
50 mm. (B) Semi-quantification of the sialic acids. Three independent mucus samples were analyzed and error bars indicate the standard deviation.
The asterisks (**) indicate statistical significance (P,0.01, Student’s t-test).
doi:10.1371/journal.pone.0110026.g002
Effects of Neuraminidase on Influenza Virus Penetration through Mucus
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e110026
conditions. By the use of these models, we were able to track the
diffusion of SIV in natural respiratory mucus. In the SPT assay,
there were two fractions based on the virus diffusion coefficient, a
mobile and an immobile fraction. The ability of SIV to detach
from mucus was attributed to the NA activities, as inhibiting NA
by the use of zanamivir significantly suppressed the liberation of
the virus from the mucus network (Fig. 6A, 6B). This is also in line
with a previous report by Matrosovich et al [26], which describes
that blocking of the NA activities by oseltamivir efficiently
inhibited influenza A viruses from infecting the differentiated
human airway epithelium cultures which were probably covered
by mucin secretions. Furthermore, exogenous neuraminidase was
shown to promote both the microscopic diffusion and macroscopic
penetration detected by the SPT and virus in-capsule-mucus
penetration system (Fig. 6). This does not only confirm the
beneficial effect of neuraminidase on releasing SIV from
respiratory mucus, but also highlights bidirectional synergistic
interactions between influenza virus and bacterial infections. The
influenza virus predisposition to secondary bacterial infections has
been thoroughly studied [27,28], however, little information exists
regarding the impact of bacterial neuraminidase on influenza virus
entry and transmission, and further research is needed.
Neuraminidase was indicated to play a role in the SIV releasing
from mucus, however, two fractions of viral motion in the mucus
lead to a discussion of the way that the virus binds to the mucus.
Mucins are the major constitute of mucus and are highly
decorated by glycans terminated by sialic acids, thus they are
likely to be attributed to the immobilization of SIV in porcine
respiratory mucus. Mucins may play direct and indirect roles in
host defense distinct from their ability to form adhesion decoys. In
Figure 3. Purity of SIV determined by Dio labeling and immunofluorescence staining. (A) Confocal microscopy of the double staining of
the virus preparations. Green represents Dio labeled particles; viral antigens are shown in red. Merged signals represent virus particles which are also
labeled with Dio. (B) Bands form in the discontinuous iodixanol gradient separation. Three bands were identified, named Band 1, Band 2 and Band 3
from up downwards. (C) Ratio of double positive particles versus Dio positive particles for the particles from three different bands. Three independent
experiments were performed and error bars indicate the standard deviation.
doi:10.1371/journal.pone.0110026.g003
Table 1. Characteristics of SIV and Dio-labeled SIV.
Zeta potential (mV) Diameter (nm) Infectivity (TCID50 lg/ml) HA titer NA activity (RFU
*)
SIV 224.263.8 101.862.9 8.760.43 256 3401763250
Dio-Labeled SIV 228.165.1 113.562.5 8.560.23 256 3095064172
*RFU= Relative Fluorescence Units.
doi:10.1371/journal.pone.0110026.t001
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addition to mucins, the aqueous mucus layer consists of a great
number of host defense agents including lysozyme, lactoferrin,
secretory IgA (sIgA), collectins, defensins, cathelicidins, histatins
and surfactant proteins [29–31]. These molecules may function by
binding the virions in a receptor-independent pattern. It has been
shown that surfactant protein D (SP-D) binds via a carbohydrate
Figure 4. Diffusion coefficient of SIV in mucus and comparison with PRV and 100 nm PEGylated beads. (A) Distributions of the
apparent diffusion coefficient of SIV, PRV and 100 nm PEGylated beads in porcine respiratory mucus. Trajectories of 8 steps were analyzed for each of
the 1500 diffusion coefficients. Distributions were refined with MEM. Dashed line indicates the boundary of mobile and immobile diffusion. (B)
Average diffusion coefficient of SIV, PRV and 100 nm PEGylated beads. Data were obtained from three independent experiments, and error bars
indicate the standard deviation. The asterisks (**) indicate statistical significance (P,0.01, by Student’s t-test).
doi:10.1371/journal.pone.0110026.g004
Figure 5. Penetration of SIV through porcine respiratory mucus. (A) Confocal microscopic analysis of the virus penetration. Representative
confocal photomicrographs of the penetration of SIV at 2, 10 and 30 min post virus addition. Mucin 5AC and SIV antigens were visualized by red and
green color, respectively. (B) Penetration depths of SIV with time. Hundred and twenty measurements were obtained from three independent mucus
samples. (C) Average penetration depth of SIV at 2, 10 and 30 min post virus addition. Three independent experiments were performed. Error bars
indicate the standard deviation. The asterisk (*) indicates statistical significance (P,0.05, by Student’s t-test).
doi:10.1371/journal.pone.0110026.g005
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Figure 6. Effects of NAI and Arthrobacter ureafaciens neuraminidase (AUNA) on microscopic diffusion and macroscopic penetration
of SIV in porcine respiratory mucus. (A) Distribution of diffusion coefficient of NAI, AUNA and mock treated SIV in mucus. 1500 trajectories were
analyzed. Distributions were refined with MEM. (B) Proportion of mobile fraction (Da.0.2 mm2/s) of NAI, AUNA and mock treated SIV in mucus. Error
bars represent the standard deviation from three independent experiments. The asterisks (**) indicate statistical significance (P,0.01, by Student’s t-
test) (C) Distribution of the penetration depth of NAI, AUNA and mock treated SIV through mucus at 30 min post virus addition. Hundred and twenty
measurements were performed on three independent mucus samples. (D) Average penetration depth of NAI, AUNA and mock treated SIV through
mucus at 30 min post virus addition. Three independent samples were performed, and error bars indicate the standard deviation. The asterisks (**
and *) indicate statistical significance (P,0.01, and P,0.05, respectively, by Student’s t-test).
doi:10.1371/journal.pone.0110026.g006
Figure 7. Effects of NA on SIV binding to porcine respiratory mucus shown by confocal microscopy. (A) Virions (green) bound to mucus
sections in the presence or absence (Mock) of Zanamivir (NAI) or Arthrobacter ureafaciens neuraminidase (AUNA). (B) Quantification of viral particles
bound to mucus (per 105 mm2). The error bars indicate the standard deviation from 3 independent experiments. The asterisks (** and *) show the
significance difference (P,0.01, and P,0.05 by Student’s t-test).
doi:10.1371/journal.pone.0110026.g007
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recognition domain in a Ca2+-dependent manner to N-linked
high-mannose carbohydrates present on the HA and NA of the
influenza viruses [32]. In addition, sIgA is retained at high
concentrations in mucus where it can efficiently trap the
pathogens. Last but not least, defensins are of great interest with
respect to respiratory viral infection. Human defensins have been
shown to bind several types of viruses and inhibit the entry of the
viruses to target cells [33,34]. These components may be retained
in mucus by direct binding with mucins or by the biophysical
properties of mucus and thus become part of the gel network and
provide an immobilized reservoir of protective effectors. Alterna-
tively, it is possible that the viral particles that were immobilized in
the mucus were actually incomplete or defective virions or became
inactive while being prepared. The production of defective
particles has been reported for influenza A viruses [35,36].
However, the approach of distinguishing active and inactive
virions in an entity has not been readily achieved, and will be
further examined.
While vaccination remains the primary option for the preven-
tion and control of influenza, anti-influenza virus drugs are
considered as a complementary approach, as vaccine production
may not be rapidly achieved. Our findings provide experimental
evidence for the essential role of NA in influenza virus penetration
through the respiratory mucus. Blocking the NA activities clearly
suppressed the movement of virus in mucus (Fig. 6), illustrating
that NA played a role in removing the sialic acids on mucins,
which may enable the virus to gain access to the cellular receptors.
This suggests the usefulness of neuraminidase inhibitors as
prophylactic treatment for influenza. On the other hand,
preventative treatment with oseltamivir (Tamiflu) failed to protect
the lung from virus replication or inflammation in an in vivo
influenza infection study in pigs despite reduced clinical symptoms
and virus shedding [37]. This highlights the complexity of the in
vivo situation and the minimal benefits neuraminidase inhibitors
may have.
The ability of an influenza virus passing through the mucus may
serve as a determinant for influenza virus transmission in addition
to efficient virus attachment, high potential of replication and low
infectious dose required [5,38,39]. Combining the study of Cohen
et al. [19], it can be noticed that human influenza viruses could
bind and be released from human salivary mucins but not from
porcine submaxillary mucins, whereas, swine influenza virus was
able to escape from porcine airway mucus, suggesting there may
be different interactions between different influenza viruses and
the mucus of different species. A balance of binding to and
releasing from the mucin sialic acids, which is determined by the
functional balance of HA and NA, may influence how efficiently
the virus avoids sticking to mucus. Fluorescence lectin staining on
mucus cryosection showed that both a2,3- and a2,6-SA were
present in the porcine respiratory mucus, with distinct predom-
inance for the latter (Fig. 2). The binding profile of the SIV strain
was not investigated in this study, however, it has been well
documented that swine influenza virus isolates, especially those
with the avian-like H1 and H3 hemagglutinins showed receptor
specificity for both a2,3- and a2,6-sialylated glycans [40–42].
Probably the mucus provides sufficient amount of receptors for
SIV binding. The binding of SIV via HA to the porcine
respiratory mucus was proved in the present study, and the
amount of viral or exogenous NA indeed modulated the extent of
viral binding to and releasing from the porcine mucus (Fig. 7).
Concerning the releasing effect, NA which mediates the process
also has a substrate preference. It was demonstrated that NA of
human and swine influenza viruses have a preferential specificity
for a2,3-SA although they cleave both linked sialylated glycans
[43,44]. Therefore, we assume that the sialic acids in respiratory
mucus secretions may exert an effect on influenza virus
transmission.
Since the majority of viral particles were incapable of
penetrating through the mucus layer, why do influenza viruses
invade the respiratory tract of the animals after all [1,3,45]? Based
on our experimental findings and present literature, we propose
several strategies the influenza viruses may use to overcome the
mucus barrier and find their way to establish infection:
(1) Production of enzymes that aid the virus movement
through the mucus. Influenza virus binds to and uses
sialic acid-containing molecules as receptors. It is because
of this capability that influenza virus has evolved a second
viral surface protein, neuraminidase, as a receptor-
destroying enzyme that cleaves sialic acid, allowing the
virus to be released after binding to sialic acid-containing
molecules that do not lead to viral infection. This strategy
is utilized as well by many other microbes, such as E.
histolytica [46,47], Vibrio cholerae [48], Helicobacter
pylori [49], Reovirus [50] and Coronavirus [51], to
subvert or avoid the mucus barrier. The production of
enzymes, including mucinase, sialidase, glycosidase,
elastase, and hydrolase, which are capable of degrading
mucin core proteins and mucin carbohydrates facilitates
microbes to swim through the mucus layer. Furthermore,
the enzymes that the microbes produce may also facilitate
the invasion of other pathogens. In women with bacterial
vaginosis, the overgrowth of anaerobic gram-negative
bacteria that produce sialidase, glycosidases and other
mucin-degrading enzymes causes a breakdown in the
barrier properties of cervicovaginal mucus, thereby
destroying the mucus gel and helping other sexually
transmitted pathogens such as human immunodeficiency
virus (HIV) to invade [52].
(2) The use of abundant and ubiquitous molecules as
receptors. Although there may be a risk of binding to
decoy receptors, the use of abundant and ubiquitous
molecules as receptors provides the apparent advantage
to the virus for allowing infection of multiple cell types
and species. This can result in a low minimal infectious
dose for initial infection. Based on the data of diffusion
and penetration, the effects of the mucus network that
virions encounter are so extreme that only a part of the
particles can escape and reach susceptible target cells
ultimately. Thus the viruses which require lower minimal
infectious doses for the same tissues may gain higher
chance to establish an infection.
(3) Spreads via aerosol. The slow settle of aerosols in the air
can cause prolonged contact of the virus with the
respiratory tract which benefits the virus penetration
through the mucus layer. Furthermore, aerosol droplets
can travel much more efficiently to the lower respiratory
tract and the mucociliary apparatus may need a longer
time to transport and exclude the virions out of the
respiratory tract, which increases the chance of these
viruses to penetrate through the mucus layer and reach
the target cells eventually.
The issues on if SIV would be able to penetrate through the
porcine respiratory mucus and if the neuraminidase would
contribute to move the virus through the mucus layer have been
addressed. However, the ability of the viral neuraminidase to
cleave sialic acid from mucus has not been investigated due to
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technical limitation. The viscous property impedes the separation
of the free sialic acids from the mucus even if they would have
been cleaved by the viral neuraminidase. Investigating the role of
influenza virus neuraminidase in the cleavage of sialic acid from
mucus may shed some light on unravelling the mechanism of
influenza pneumonia. Hence the effect of influenza virus
neuraminidase on mucus needs to be studied.
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